MA45625A - Nouveaux régimes posologiques pour conjugués anticorps-médicaments à base d'anticorps anti-axl - Google Patents

Nouveaux régimes posologiques pour conjugués anticorps-médicaments à base d'anticorps anti-axl

Info

Publication number
MA45625A
MA45625A MA045625A MA45625A MA45625A MA 45625 A MA45625 A MA 45625A MA 045625 A MA045625 A MA 045625A MA 45625 A MA45625 A MA 45625A MA 45625 A MA45625 A MA 45625A
Authority
MA
Morocco
Prior art keywords
antibody
axl
dosage regimes
new dosage
based conjugate
Prior art date
Application number
MA045625A
Other languages
English (en)
Inventor
Ulf Forssmann
Steen Lisby
Nedjad Losic
Original Assignee
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2016/066353 external-priority patent/WO2017009258A1/fr
Application filed by Genmab As filed Critical Genmab As
Publication of MA45625A publication Critical patent/MA45625A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un conjugué anticorps-médicament (adc) basé sur un anticorps se liant à l'axl humain et des compositions pharmaceutiques comprenant l'adc à utiliser dans le traitement d'un cancer, comprenant l'administration à un sujet d'une dose hebdomadaire d'environ 0,45 mg / kg à environ 2,0 mg / kg. Kg d'adc une fois par semaine pendant trois semaines consécutives, suivies d'une période de repos d'une semaine sans aucune administration d'adc, de sorte que la durée de chaque cycle est de 28 jours, période de repos incluse.
MA045625A 2016-07-08 2017-07-07 Nouveaux régimes posologiques pour conjugués anticorps-médicaments à base d'anticorps anti-axl MA45625A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2016/066353 WO2017009258A1 (fr) 2015-07-10 2016-07-08 Conjugués anticorps-médicament spécifiques d'axl pour le traitement du cancer
US201662410984P 2016-10-21 2016-10-21

Publications (1)

Publication Number Publication Date
MA45625A true MA45625A (fr) 2019-05-15

Family

ID=60921579

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045625A MA45625A (fr) 2016-07-08 2017-07-07 Nouveaux régimes posologiques pour conjugués anticorps-médicaments à base d'anticorps anti-axl

Country Status (5)

Country Link
US (1) US20190233522A1 (fr)
EP (1) EP3481868A1 (fr)
JP (1) JP2019524713A (fr)
MA (1) MA45625A (fr)
WO (1) WO2018007592A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2991805A1 (fr) * 2015-07-10 2017-01-19 Genmab A/S Conjugues anticorps-medicament specifiques d'axl pour le traitement du cancer
JP2019505520A (ja) 2016-01-13 2019-02-28 ゲンマブ エー／エス 抗体およびその薬物コンジュゲートの製剤
MX393780B (es) 2017-01-17 2025-03-24 Heparegenix Gmbh Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos
MA52657A (fr) * 2018-04-10 2021-02-17 Genmab As Anticorps spécifiques d'axl pour le traitement du cancer
EP3856783A1 (fr) * 2018-09-26 2021-08-04 Genmab A/S Anticorps spécifiques d'axl pour le traitement du cancer du poumon non à petites cellules
EP4099989A4 (fr) 2020-02-06 2023-12-13 University of Pittsburgh - Of the Commonwealth System of Higher Education Récepteurs de lymphocytes t ciblant des protéines de réparation d'adn défectueux
US10822379B1 (en) 2020-03-12 2020-11-03 University of Pittsburgh—of the Commonwealth System of Higher Education Molecules that bind to SARS-CoV-2
EP4230222A1 (fr) 2022-02-17 2023-08-23 Oxsonics Limited Polythérapie avec un conjugué anticorps anti-axl-pbd et nanocups

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
AU2006317242A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
CN101616671A (zh) * 2007-01-19 2009-12-30 卫材R&D管理有限公司 胰腺癌治疗用组合物
CA2749115C (fr) * 2009-01-09 2022-06-21 Seattle Genetics, Inc. Regimes posologiques hebdomadaires pour des conjugues anticorps anti-cd30 vc-pab-mmae - medicament
WO2014174111A1 (fr) 2013-04-26 2014-10-30 Pierre Fabre Medicament Conjugué anticorps anti-axl-médicament et son utilisation pour le traitement du cancer
MX2016000131A (es) * 2013-06-28 2016-06-15 Bind Therapeutics Inc Nanoparticulas polimericas de docetaxel para el tratamiento de cancer.
WO2015157297A1 (fr) * 2014-04-08 2015-10-15 Seattle Genetics, Inc. Dosage optimal d'un conjugué médicament-anticorps anti-cd19
IL296633A (en) 2014-07-11 2022-11-01 Genmab As Antibodies that bind axl
ES2764299T3 (es) * 2014-12-09 2020-06-02 Inst Nat Sante Rech Med Anticuerpos monoclonales humanos contra AXL
CA2991805A1 (fr) * 2015-07-10 2017-01-19 Genmab A/S Conjugues anticorps-medicament specifiques d'axl pour le traitement du cancer

Also Published As

Publication number Publication date
EP3481868A1 (fr) 2019-05-15
JP2019524713A (ja) 2019-09-05
US20190233522A1 (en) 2019-08-01
WO2018007592A1 (fr) 2018-01-11

Similar Documents

Publication Publication Date Title
MA45625A (fr) Nouveaux régimes posologiques pour conjugués anticorps-médicaments à base d'anticorps anti-axl
WO2017141104A8 (fr) Procédé d'induction d'une réponse immunitaire prolongée
RU2011110765A (ru) Фармацевтическая композиция энтакапона или его солей пролонгрированного высвобождения
Kukushkin et al. Results of a randomized double blind parallel study on the efficacy and safety of tolpersione in patients with acute nonspecific low back pain
MX2007006707A (es) Acidos grasos omega-3 y agente dislipidemico para terapia lipidica.
RU2014111069A (ru) Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение
JP2013231087A5 (fr)
MA50201B1 (fr) Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
JP2019530706A5 (fr)
JP2016505050A5 (fr)
PH12019500516A1 (en) Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof
JP2018506533A5 (fr)
RU2007104774A (ru) Комбинация анти-вич ингибиторов обратной транскриптазы и протеазы
MX391191B (es) Composiciones de liberación extendida de onapristona y métodos.
US9687518B2 (en) Medicament for treating muscle and skeletal diseases
Patil et al. Innovative strategies in the diagnosis and treatment of tuberculosis: a patent review (2014–2017)
White et al. Effects of naproxcinod on blood pressure in patients with osteoarthritis
BE1002256A3 (fr) Medicaments.
JP2019524782A5 (fr)
MA49754B1 (fr) Méthodes de traitement de symptômes de gastroparésie au moyen de velusetrag
RU2016145411A (ru) Комбинация брекспипразола и налмефена, и ее применение для лечения синдрома химической зависимости
JP2015515971A5 (fr)
HRP20160811T1 (hr) Upotreba odiparcila u liječenju mukopolisaharidoze
Bartt Leprosy (Hansen’s disease)